Masimo's (MASI) Noninvasive Continuous PVi Favored by New Study
Masimo (MASI) reports study findings that will aid clinicians in getting meaningful information with respect to monitoring the volume status in critic...
Masimo Corporation MASI recently announced the findings of a study published in the Turkish Journal of Emergency Medicine, wherein researchers explored the utility of noninvasive, continuous Masimo Pleth Variability Index (PVi) when it comes to monitoring volume status and changes in spontaneously breathing patients who are undergoing hemodialysis (HD). Per the findings, a strong correlation has been found between change in PVi and the volume of fluid removed.
Based on the positive outcome, PVi might offer clinicians useful information for monitoring the volume status in critically ill patients with spontaneous breathing.
It is worth mentioning that in the United States, PVi has clearance to be utilized as noninvasive, dynamic indicator of fluid responsiveness in select populations of mechanically ventilated adult patients.
The latest favorable study outcome is likely to provide a boost to Masimo’s non-invasive patient monitoring solutions portfolio.
More on the Study
There have been more than 100 independent studies demonstrating the utility of PVi as an indicator of fluid responsiveness. For this particular study, researchers enrolled 60 adult patients with end-stage renal disease receiving routine HD — wherein fluid is removed simultaneously with the removal of waste solutes — and had a median of 3,500 cc of fluid removed during HD.
Image Source: Zacks Investment Research
PVi was measured utilizing a Masimo pulse oximetry sensor attached to a Masimo Root monitor, before and after HD, while changes in PVi were compared to the amount of fluid removed during the session.
It is important to mention here that the reliability of PVi in estimating fluid responsiveness is variable and can be influenced by several patient, procedure and device-associated factors.
Per a report by Market Data Forecast, the global fluid management systems market is projected to be worth $14.74 billion by 2026 from $11.12 billion in 2021, at a CAGR of 5.8% during the forecast period. Given the market potential, the positive study outcome is likely to provide a significant boost to Masimo’s patient monitoring business profile.
This month, the company announced the findings of a study published in the Journal of Pain & Relief wherein researchers explored the utility of Masimo Bridge in reducing postoperative opioid needs in patients undergoing kidney donor surgery. Bridge, an auricular field nerve stimulator, was found to be associated with significant reductions in opioid use and pain after surgery.
In July, the company announced robust second-quarter 2021 results where it recorded a strong rebound in sensor sales (on the back of steady expansion of monitoring in hospitals), along with robust order shipments.
The same month, Masimo announced the release of its latest and most advanced rainbow SET board, MX-7. The board has been engineered for integration into numerous multi-parameter monitors available with the company’s various original equipment manufacturing partners.
Shares of the Zacks Rank #3 (Hold) company have gained 29% in the past year compared with the industry’s growth of 14.9%.
Stocks to Consider
Some better-ranked stocks from the broader medical space are Henry Schein, Inc. HSIC, Envista Holdings Corporation NVST and Merit Medical Systems, Inc. MMSI, each currently carrying a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Henry Schein’s long-term earnings growth rate is estimated at 13.9%.
Envista Holdings’ long-term earnings growth rate is estimated at 27.4%.
Merit Medical’s long-term earnings growth rate is projected at 13.6%.
Tech IPOs With Massive Profit Potential
In the past few years, many popular platforms and like Uber and Airbnb finally made their way to the public markets. But the biggest paydays came from lesser-known names.
For example, electric carmaker X Peng shot up +299.4% in just 2 months. Think of it this way…
If you had put $5,000 into XPEV at its IPO in September 2020, you could have cashed out with $19,970 in November.
With record amounts of cash flooding into IPOs and a record-setting stock market, this year’s lineup could be even more lucrative.See Zacks Hottest Tech IPOs Now >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Henry Schein, Inc. (HSIC): Free Stock Analysis Report
Masimo Corporation (MASI): Free Stock Analysis Report
Merit Medical Systems, Inc. (MMSI): Free Stock Analysis Report
Envista Holdings Corporation (NVST): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research